1160221-25-9 Usage
General Description
Benzoic acid, 3-[6-[[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]aMino]-3-Methyl-2-pyridinyl]-, 1,1-diMethylethyl ester is a chemical compound with a complex structure containing multiple functional groups, including benzoic acid, a fluorinated benzodioxole, a cyclopropyl group, and an amino pyridinyl group. Benzoic acid, 3-[6-[[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]aMino]-3-Methyl-2-pyridinyl]-, 1,1-diMethylethyl ester, also known as a modified benzoate ester, features the ester of benzoic acid and a tert-butyl group. The presence of fluorine atoms and a dioxole ring suggests that it might have unique properties and reactivity. Its specific uses and properties further depend on the context in which it is applied, and not much information is available about its specific applications in different fields. Benzoic acid, 3-[6-[[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]aMino]-3-Methyl-2-pyridinyl]-, 1,1-diMethylethyl ester is not widely discussed in scientific literature, suggesting that it may be a niche or lesser-known substance.
Check Digit Verification of cas no
The CAS Registry Mumber 1160221-25-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,6,0,2,2 and 1 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1160221-25:
(9*1)+(8*1)+(7*6)+(6*0)+(5*2)+(4*2)+(3*1)+(2*2)+(1*5)=89
89 % 10 = 9
So 1160221-25-9 is a valid CAS Registry Number.
1160221-25-9Relevant articles and documents
METHODS OF TREATMENT FOR CYSTIC FIBROSIS
-
, (2020/06/05)
This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. (I) The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.
MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR
-
, (2018/06/30)
Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
SOLID FORMS OF LUMACAFTOR, ITS SALTS AND PROCESSES THEREOF
-
Page/Page column 46-47, (2017/11/04)
Aspects of the present application relate to solid forms of Lumacaftor, its salts and processes thereof. Specific aspects of the present application relate to alternate processes for the preparation of Lumacaftor and intermediates thereof. Present application further relates to the solid forms of Lumacaftor and its salts.
